ALHC · NASDAQ · Medical - Healthcare Plans

Alignment Healthcare (ALHC)

Medicare Advantage plans paired with data-driven care coordination for seniors.

$7.94
vs last close−0.40 (−4.74%)
Loading prices…

Alignment Healthcare, Inc.ALHC
Health Care

Sells Medicare Advantage plans for seniors, earning mainly fixed monthly CMS payments while assuming members' covered-care costs. AVA analytics, Care Anywhere clinical teams, provider networks, and concierge support coordinate care across a single healthcare-services segment.

Offers Medicare Advantage coverage to seniors through Alignment Health Plan, including HMO, PPO, and special-needs designs across selected markets in California, North Carolina, Nevada, Arizona, and Texas. Revenue comes mainly from fixed monthly CMS payments, while the insurer assumes responsibility for covered care and related costs.

Combines the AVA data platform with Care Anywhere clinical teams, local provider networks, the ACCESS On-Demand Concierge card, and round-the-clock member service to identify higher-risk members and coordinate care at home or remotely. Operates as one healthcare-services segment. The model depends on annually renewed CMS contracts, risk-adjusted payments and Star Ratings, accurate medical-cost forecasting, and provider-network performance.

Company facts

CEOJohn E. Kao
ListedMar 26, 2021
ExchangeNASDAQ
HeadquartersOrange, CA
CountryUnited States
Employees1,849
CIK0001832466
ISINUS01625V1044

Market cap$1.73B
EPS (ttm)$0.1866
P/E (ttm)44.64
ROE20.0%
P/B6.52
P/S0.3775
Dividend yieldDiv yield
Beta0.41vs XLV 0.68

Price target$19.00+128.1%Average of 16 analysts
ConsensusBuy14 of 16 analysts
Ratings

Target rangeAs of Sep 21, 2026

Latest analyst notes

DateFirmActionPriorCurrent
Aug 3, 2026Raymond JamesDowngrade
Rating: Strong BuyTarget: $22
Rating: OutperformTarget: $19
May 26, 2026BarclaysReiterate
Rating: Target: $19
Rating: Equal WeightTarget: $16
May 7, 2026Raymond JamesTarget
Target: $10
Target: $22
May 1, 2026UBSReiterate
Rating: Target: $21
Rating: NeutralTarget: $22
May 1, 2026BarclaysReiterate
Rating: Target: $18
Rating: Equal WeightTarget: $19

Next report
Oct 29, 26
in 37 days
EPS estimate
−$0.03
Revenue estimate
$1.31B
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Feb '25May '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported−$0.16−$0.05$0.07$0.02−$0.05$0.05$0.17Pending
Estimate−$0.18−$0.12−$0.07−$0.01−$0.15$0.01$0.13−$0.03
Surprise+11.1%+58.3%+200.0%+300.0%+66.7%+400.0%+31.8%

RevenueReportedEstimate

Feb '25May '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported$701.2M$926.9M$1.02B$993.7M$1.01B$1.24B$1.34BPending
Estimate$677.4M$888.3M$960.0M$980.9M$1.00B$1.22B$1.31B$1.31B
Surprise+3.5%+4.4%+5.8%+1.3%+0.9%+1.4%+2.0%
Estimate−$0.03
ReportedDue Oct 29, 2026
Estimate$1.31B
ReportedDue Oct 29, 2026
View details

Debt to equity124.70%
Current ratio169.80%

ProfitabilityRevenueNet incomeNet margin

Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Revenue$692.4M$701.2M$926.9M$1.02B$993.7M$1.01B$1.24B$1.34B
Net income−$26.4M−$31.1M−$9.1M$15.7M$3.7M−$11.0M$11.4M$36.6M
Net margin0.0%0.0%0.0%1.5%0.4%0.0%0.9%2.7%

GrowthOperating income

Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Operating income−$19.5M−$22.5M−$5.4M$22.7M$7.7M−$10.3M$15.5M$42.1M
YoY growthLoss narrowedLoss narrowedLoss narrowedTurned profitTurned profitLoss narrowedTurned profit+85.1%

Balance sheet, Jun 30, 2026Cash & short-term investments $701.7M · Total debt $330.5M · Total assets $1.28B · Shareholders' equity $265.1M

Revenue
$1.34B
Operating income
$42.1M
Net income
$36.6M
View details

No dividends on record.

Institutions107.98%223.99M shares
338 holders · as of Jun 30, 2026
Insiders9.04%18.75M shares
21 holders · as of Sep 16, 2026
Adds to117.02%

207.44M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing

These groups come from separate filings that can overlap, so they add to 117.02%; nothing is left for Other.

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesDate
BlackRock, Inc.Institution
9.32%19.34Mas of Jun 30, 2026
Wellington Management Group LLPInstitution
9.05%18.78Mas of Jun 30, 2026
FMR LLCInstitution
6.71%13.92Mas of Jun 30, 2026
Qatar Investment AuthorityInsider
6.39%13.25Mfiled Sep 24, 2025
T. Rowe Price Investment Management, Inc.Institution
6.32%13.12Mas of Jun 30, 2026

Insider tradesForm 4

DateInsiderRoleSharesAvg price
Sep 17, 2026Joseph S. Konowieckidirector, officer: EVP, Corporate Affairs−23,511$8.61
Sep 14, 2026John E. Kaodirector, officer: Chief Executive Officer−27,400$13.00
Sep 11, 2026John E. Kaodirector, officer: Chief Executive Officer−385,270$12.68
Sep 10, 2026John E. Kaodirector, officer: Chief Executive Officer−172,600$12.96
Sep 11, 2026Dawn Christine Maroneyofficer: President−122,707$12.68
View details

  • UnitedHealth Group

    Largest MA rival with national scale, Part D, and Optum support

  • Humana

    Senior-focused MA carrier with large value-based care membership

  • CVS Health

    Aetna MA plans add national pharmacy and PDP channel pressure

  • Elevance Health

    Anthem and Wellpoint MA networks challenge regional plan growth

  • Centene

    Wellcare overlaps in MA, PDP, and value-conscious senior plans

  • Clover Health

    Tech-enabled MA peer built around Clover Assistant

  • Molina Healthcare

    Dual-eligible Medicare operator with narrowing MAPD overlap

Compare

CompanyPriceChange
Alignment Healthcare$7.94−4.74%$1.73B44.628.70.4+31.6%
UnitedHealth Group$374.11−0.91%$342.88B24.317.50.8+0.4%
Humana$371.97−1.75%$45.39B35.930.20.3+26.2%
CVS Health$87.28−0.37%$111.77B23.210.80.3+7.3%
Elevance Health$403.30−1.47%$88.77B18.214.80.4+0.8%
Centene$63.45−2.38%$32.10B14.10.2+9.9%
Clover Health$4.68+2.97%$2.35B75.21.0+55.6%
Molina Healthcare$191.18−3.35%$10.33B1,041.127.10.2−4.8%
Median24.317.50.3+7.3%